Dexamethasone controlled release - Taiwan Liposome Company

Drug Profile

Dexamethasone controlled release - Taiwan Liposome Company

Alternative Names: ProDex; TLC-399

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Taiwan Liposome Company
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinal oedema

Most Recent Events

  • 03 Apr 2017 Taiwan Liposome plans a phase II trial for Retinal oedema in USA (NCT03093701)
  • 27 Dec 2016 Phase-II clinical trials in Retinal oedema in Taiwan (Intravitreous) (Taiwan Liposome Company pipeline, December 2016)
  • 07 Jan 2015 The Ministry of Economic Affairs grants a subsidy worth $NT17.6 million for the phase I/II programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top